FDA Hosts Workshop to Improve Community Access to Life-Saving Epinephrine
Published Date: 11/24/2025
Notice
Summary
The FDA is hosting a workshop on December 16, 2025, to talk about making epinephrine easier to get for people who might have severe allergic reactions (anaphylaxis). This effort aims to save lives by getting epinephrine into more hands, especially in community places. Everyone can join online or in person and share their thoughts by January 16, 2026, helping shape future access and safety improvements.
Analyzed Economic Effects
6 provisions identified: 0 benefits, 6 costs, 0 mixed.
Many at-risk patients lack or avoid epinephrine
Anaphylaxis can progress within 15 to 30 minutes and epinephrine is the only effective first-line treatment. The document says up to 5 percent lifetime prevalence in the U.S. and about 200 deaths annually, and it notes patients prescribed epinephrine may not have it available during an event or may choose not to use it because of knowledge gaps, fear, stigma, or incorrect use.
Community sites often lack epinephrine policies
Schools, workplaces, restaurants, sports facilities, transportation vehicles, and public venues may lack policies for epinephrine storage, staff training, and emergency administration. That institutional lack of preparedness can reduce access to epinephrine where anaphylaxis commonly happens.
State liability rules discourage stocking epinephrine
State laws vary regarding Good Samaritan protections for lay administration of epinephrine, and these liability concerns can discourage institutions from maintaining emergency epinephrine supplies.
Cost of epinephrine limits community availability
The document identifies economic obstacles from the cost of epinephrine products as a barrier to having community‑use epinephrine available in public settings, which can limit access during emergencies.
Rural disparities reduce timely epinephrine access
The document notes geographic disparities, especially in rural communities where pharmacies may be spread out and emergency medical services can have longer response times, which can limit timely access to epinephrine.
Prescription and provider authorization create access hurdles
The notice identifies procedural barriers such as obtaining healthcare provider authorization and maintaining a current prescription for epinephrine as factors that can limit access to this life‑saving medication.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-16296, Substances Generally Recognized as Safe
The Food and Drug Administration (FDA or we) is proposing to require the submission of generally recognized as safe (GRAS) notices for the use of a human or animal food substance purported to be GRAS under the conditions of its intended use under the Federal Food, Drug, and Cosmetic Act (FD&C Act).
2026-14073, Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign Establishments
The FDA wants to make it easier for drug makers who work in several locations to register as one company instead of many. They’re also updating rules for foreign drug companies to match new laws about handling health threats. If you’re in drug manufacturing, get ready to comment by September 11, 2026, and keep an eye on possible paperwork changes that could affect your business.
2026-13047, Establishment Registration and Product Listing for Tobacco Products
The FDA wants to make sure all tobacco product makers, both in the U.S. and abroad, register their businesses and list their products. This new rule closes a big gap by including foreign companies, helping the FDA keep better track of tobacco products for public health. Comments on this proposal are open until September 14, 2026, so affected businesses should get ready to update their info and possibly face new costs.
2026-17659, Rahim Shafa; Denial of Hearing; Final Debarment Order
The Food and Drug Administration (FDA or Agency) is denying a request for a hearing submitted by Rahim Shafa (Dr. Shafa) and is issuing an order under the Federal Food, Drug, and Cosmetic Act (FD&C Act) permanently debarring Dr. Shafa from providing services in any capacity to a person that has an approved or pending drug product application and debarring Dr. Shafa for 20 years from importing or offering for import any drug into the United States. FDA bases this order on the findings that Dr. Shafa was convicted of multiple felonies under Federal law that relate to the regulation of any drug product under the FD&C Act and the importation into the United States of any drug or controlled substance under the FD&C Act. FDA provided notice to Dr. Shafa of the proposed debarment and an opportunity to request a hearing. Dr. Shafa submitted a request for a hearing but failed to file with the Agency information and analyses sufficient to create a basis for a hearing.
2026-17676, Agency Information Collection Activities; Proposed Collection; Comment Request; Registration of Human Drug Compounding Outsourcing Facilities Under the Federal Food, Drug, and Cosmetic Act and Associated Fees
The Food and Drug Administration (FDA or Agency) is announcing an opportunity for public comment on the proposed collection of certain information by the Agency. Under the Paperwork Reduction Act of 1995 (PRA), Federal Agencies are required to publish notice in the Federal Register concerning each proposed collection of information, including each proposed extension of an existing collection of information, and to allow 60 days for public comment in response to the notice. This notice solicits comments on the information collection pertaining to the registration of human drug compounding outsourcing facilities under the Federal Food, Drug, and Cosmetic Act (FD&C Act) and associated fees.
2026-17598, Agency Information Collection Activities; Proposed Collection; Comment Request; Focus Groups and Interviews as Used by the Food and Drug Administration
The Food and Drug Administration (FDA or Agency) is announcing an opportunity for public comment on the proposed collection of certain information by the Agency. Under the Paperwork Reduction Act of 1995 (PRA), Federal Agencies are required to publish notice in the Federal Register concerning each proposed collection of information, including each proposed extension of an existing collection of information, and to allow 60 days for public comment in response to the notice. This notice solicits comments on the generic collection of focus group information as used by FDA for all FDA-regulated products.
Previous / Next Documents
Previous: 2025-20657, Carroll County Energy LLC; Notice of Institution of Section 206 Proceeding And Refund Effective Date
The Federal Energy Regulatory Commission is checking if Carroll County Energy LLC’s rates are fair or not. If they find the rates unfair, refunds could start from November 24, 2025. Anyone interested has 21 days to speak up and get involved in the process.
Next: 2025-20659, Agency Information Collection Activities; Proposed eCollection eComments Requested; DEA Voluntary Wellness Program Healthcare Provider Clearance
The Drug Enforcement Administration (DEA) wants your feedback on a new form for their Voluntary Wellness Program aimed at healthcare providers. They’re asking for comments by December 24, 2025, to make sure the form is easy to use and not too time-consuming. This helps the DEA improve the program without costing extra money or hassle for those involved.